mTOR: A Cellular Regulator Interface in Health and Disease
Open Access
Abstract
The mechanistic target of Rapamycin (mTOR) is a ubiquitously-conserved serine/threonine kinase, which has a central function in integrating growth signals and orchestrating their physiologic effects on cellular level. mTOR is the core component of differently composed signaling complexes that differ in protein composition and molecular targets. Newly identified classes of mTOR inhibitors are being developed to block autoimmune diseases and transplant rejections but also to treat obesity, diabetes, and different types of cancer. Therefore, the selective and context-dependent inhibition of mTOR activity itself might come into the focus as molecular target to prevent severe diseases and possibly to extend life span. This review provides a general introduction to the molecular composition and physiologic function of mTOR complexes as part of the Special Issue “2018 Select Papers by Cells’ Editorial Board Members”.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (FOR1905)
This publication has 212 references indexed in Scilit:
- Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors Everolimus and Temsirolimus in Cancer Patients: A Meta-AnalysisPLOS ONE, 2013
- TOR Signaling and Rapamycin Influence Longevity by Regulating SKN-1/Nrf and DAF-16/FoxOCell Metabolism, 2012
- mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP PathwayCell, 2011
- Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathwayBiochemical and Biophysical Research Communications, 2010
- Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino AcidsCell, 2010
- Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila melanogasterCell Metabolism, 2010
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their SurvivalCell, 2009
- mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in MiceCancer Cell, 2009
- SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell GrowthCell Metabolism, 2008
- Rapamycin and mTOR kinase inhibitorsJournal of Chemical Biology, 2008